69 related articles for article (PubMed ID: 21690555)
1. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
Thomas X; Elhamri M; Raffoux E; Renneville A; Pautas C; de Botton S; de Revel T; Reman O; Terré C; Gardin C; Chelghoum Y; Boissel N; Quesnel B; Hicheri Y; Bourhis JH; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Blood; 2011 Aug; 118(7):1754-62. PubMed ID: 21690555
[TBL] [Abstract][Full Text] [Related]
2. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
Sljivic I; Fulford A; Ho J; Lazo-Langner A; Xenocostas A; Deotare U
Eur J Haematol; 2023 Dec; 111(6):888-894. PubMed ID: 37640495
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Garcia-Manero G; Podoltsev NA; Othus M; Pagel JM; Radich JP; Fang M; Rizzieri DA; Marcucci G; Strickland SA; Litzow MR; Savoie ML; Medeiros BC; Sekeres MA; Lin TL; Uy GL; Powell BL; Kolitz JE; Larson RA; Stone RM; Claxton D; Essell J; Luger SM; Mohan SR; Moseley A; Appelbaum FR; Erba HP
Leukemia; 2024 Jan; 38(1):58-66. PubMed ID: 37935977
[TBL] [Abstract][Full Text] [Related]
4. Optimal Post-Remission Consolidation Therapy in Patients with AML.
Jimenez-Chillon C; Dillon R; Russell N
Acta Haematol; 2024; 147(2):147-158. PubMed ID: 38008085
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
Shepshelovich D; Edel Y; Goldvaser H; Dujovny T; Wolach O; Raanani P
Br J Clin Pharmacol; 2015 Apr; 79(4):685-91. PubMed ID: 25303309
[TBL] [Abstract][Full Text] [Related]
6. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Lamba JK; Crews KR; Pounds SB; Cao X; Gandhi V; Plunkett W; Razzouk BI; Lamba V; Baker SD; Raimondi SC; Campana D; Pui CH; Downing JR; Rubnitz JE; Ribeiro RC
Pharmacogenomics; 2011 Mar; 12(3):327-39. PubMed ID: 21449673
[TBL] [Abstract][Full Text] [Related]
7. [Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia].
Cao XX; Wang SJ; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):330-333. PubMed ID: 28468096
[No Abstract] [Full Text] [Related]
8. Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
Rebechi M; Kohlschmidt J; Mrózek K; Nicolet D; Mims AS; Blachly JS; Orwick S; Larkin KT; Oakes CC; Hantel A; Carroll AJ; Blum WG; Powell BL; Uy GL; Stone RM; Larson RA; Byrd JC; Paskett ED; Plascak JJ; Eisfeld AK
Blood Adv; 2023 Aug; 7(15):4019-4023. PubMed ID: 37196637
[No Abstract] [Full Text] [Related]
9. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
10. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.
Thomas X; Raffoux E; Renneville A; Pautas C; de Botton S; de Revel T; Reman O; Terré C; Gardin C; Chelghoum Y; Boissel N; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Socié G; Michallet M; Castaigne S; Dombret H
Leuk Res; 2012 Sep; 36(9):1112-8. PubMed ID: 22647869
[TBL] [Abstract][Full Text] [Related]
11. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.
Ye L; Gao L; Cheng Q; Guo F; He L; Yuan T; Zhu M; Ma Y; Pan M; Chu X; Ding M; Yu G
Medicine (Baltimore); 2021 Jan; 100(3):e24273. PubMed ID: 33546048
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
13. Improved Treatment Outcomes With Modified Induction Therapy in Acute Myeloid Leukemia (AML): A Retrospective Observational Study From a Regional Cancer Center.
Iqbal A; Dubey M; Randhawa AS; Khanikar D; Hazarika M; Roy PS; Dutta C; Barbhuiyan S; Deka R
Cureus; 2024 Jan; 16(1):e53303. PubMed ID: 38435958
[TBL] [Abstract][Full Text] [Related]
14. AML consolidation therapy: timing matters.
Reimann AM; Schalk E; Jost F; Mougiakakos D; Weber D; Döhner H; Récher C; Dumas PY; Ditzhaus M; Fischer T; Sager S
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13811-13821. PubMed ID: 37535164
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification.
Wang X; Liu D; Chen E; Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Geng L; Tang B; Liu H; Liu X; Zheng C
Front Oncol; 2022; 12():1070588. PubMed ID: 36727072
[TBL] [Abstract][Full Text] [Related]
16. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Hayakawa J; Nakasone H; Minakata D; Fujiwara SI; Gomyo A; Akahoshi Y; Komiya Y; Harada N; Ugai T; Kameda K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Kimura SI; Kanda J; Kako S; Kanda Y
Int J Hematol; 2022 Aug; 116(2):239-247. PubMed ID: 35429328
[TBL] [Abstract][Full Text] [Related]
18. Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.
Plesa A; Tigaud I; Hayette S; Roumier C; Thomas X
Oncol Ther; 2022 Jun; 10(1):75-84. PubMed ID: 35129793
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.
Ravikumar D; Saju H; Choudary A; Bhattacharjee A; Dubashi B; Ganesan P; Kayal S
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):31-41. PubMed ID: 35125710
[TBL] [Abstract][Full Text] [Related]
20. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Derman BA; Larson RA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
